AI Article Synopsis

  • * A clinical case is presented involving a 50-year-old woman with MM who experienced acute kidney injury over 20 days after auto-HSCT and was later diagnosed with retroperitoneal fibrosis (RPF).
  • * The patient's kidney obstruction was successfully treated with a transurethral vesicoureteral stent, restoring her renal function; the case highlights the rare occurrence of RPF post-MM transplantation and suggests the need for further investigation into the link between the two conditions.

Article Abstract

Multiple myeloma (MM) is a common hematological malignancy. Autologous hematopoietic stem cell transplantation (auto-HSCT) can significantly improve the prognosis of patients with MM, but a variety of complications may occur after transplantation. Retroperitoneal fibrosis (RPF) is a rare cause of obstructive nephropathy. Because there are no specific symptoms at the time of onset and the course of the disease is often insidious, special laboratory and instrumental examination methods are usually needed to confirm the diagnosis. This article describes the clinical case of a 50-year-old female patient diagnosed with multiple myeloma. She developed postoperative acute kidney injury (AKI) more than 20 days after transplantation and was subsequently diagnosed with retroperitoneal fibrosis. After multidisciplinary collaboration, early transurethral vesicoureteral stent placement was performed, the obstruction was relieved, and her renal function returned to normal. Reports of retroperitoneal fibrosis after multiple myeloma transplantation are relatively rare. This case report advances our understanding of these 2 diseases, and the correlation between MM and RPF warrants further exploration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transproceed.2024.08.037DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
16
retroperitoneal fibrosis
16
multiple
4
retroperitoneal
4
myeloma retroperitoneal
4
fibrosis
4
fibrosis rare
4
rare association
4
association report
4
report literature
4

Similar Publications

Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma.

Front Immunol

December 2024

Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Science, Wenzhou Medical University, Wenzhou, China.

Introduction: Challenges remain in reducing antigen escape and tumor recurrence while CAR-T cell therapy has substantially improved outcomes in the treatment of multiple myeloma. T cell receptor fusion construct (TRuC)-T cells, which utilize intact T cell receptor (TCR)-CD3 complex to eliminate tumor cells in a non-major histocompatibility complex (MHC)-restricted manner, represent a promising strategy. Moreover, interleukin-7 (IL-7) is known to enhance the proliferation and survival of T cells.

View Article and Find Full Text PDF

We report a rare case of a 45-year-old Asian male patient with concurrent multiple myeloma (MM), immune thrombocytopenic purpura (ITP), and thalassemia trait, presenting with severe thrombocytopenia, back pain, and bleeding manifestations. The diagnosis was established through a combination of laboratory findings, imaging, and bone marrow biopsy, revealing 90% plasma cell involvement and KRAS/BRCA2 mutations. Management focused on controlling ITP with corticosteroids, rituximab, and platelet transfusions while addressing immunosuppression risks.

View Article and Find Full Text PDF

This report describes a rare case of relapsed multiple myeloma in the gastrointestinal tract with aberrant CD3 expression. Upon admission for acute renal failure, the patient had abnormal computed tomography scan findings of the abdomen and pelvis. Subsequent colonoscopy found numerous polyps and masses.

View Article and Find Full Text PDF

Purpose Of The Review: This review aims to explore the pivotal role of long non-coding RNAs (lncRNAs) as epigenetic regulators in the pathogenesis of multiple myeloma (MM). Additionally, we have portrayed the dual role of lncRNAs in the epigenetic landscape of MM pathobiology.

Recent Findings: In MM, lncRNAs are pivotal for proliferation, progression, and drug resistance by acting as miRNA sponges, regulating mRNA activity through microRNA recognition elements (MREs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!